Background: The efficacy and safety of dexmedetomidine during the anesthesia induction of intracranial tumor patients remain unknown. We wondered whether loading infusion of dexmedetomidine 1 g/kg over 10 min to intracranial tumor patients was as efficient and safe as to those abdominal disease patients. Methods: Patients aged 18 -60 years, male or female, ASA I or II, scheduled for intracranial tumor resection (Group N, n = 30) or abdominal operation (Group A, n = 30) were enrolled in this observational trial. Dexmedetomidine was administrated with a loading dosage of 1 g/kg over 10 min following with continuous infusing of 0.5 g/kg/h. Fentanyl, propofol and rocuronium were sequentially administered for anesthesia induction. Heart rate (HR), blood pressure (BP), pulse oxygen saturation (SpO 2 ), bispectral index (BIS) and other adverse effects were recorded from the beginning of loading infusion of dexmedetomidine to the end of endotracheal intubation. Results: Among with loading infusion, HR and BIS value decreased and were significantly lower at the end of infusion than before infusion (P < 0.01), but BP did not (P > 0.05). One patient of Group N dropped out from this trial because of a serious headache. 14 of 29 patients during dexmedetomidine loading infusion suffered hypoxemia (SpO 2 < 90%) in Group N, which was higher than 6 of 30 of in Group A (P < 0.05). No other side effects were recorded. Conclusion: A loading dosage of 1 g/kg of dexmedetomidine was not suitable for the anesthesia induction of intracranial tumor patients as compared to patients undergoing abdominal operation.
Introduction
Dexmedetomidine, a highly selective α 2 -adrenoreceptor agonist, is widely used as a sedative or an adjuvant agent for anesthesia induction and maintenance [1] [2] [3] [4] [5] [6] . Patients sedated with dexmedetomidine could well tolerate the endotracheal intubation. When using as sedative, dexmedetomidine can increase hemodynamic stability, cause little respiratory depression and allow a rapid recovery [1, 7, 8] .
Preliminary data of the perioperative usage of dexmedetomidine in patients undergoing neurosurgery have indicated that preoperative usage of dexmedetomidine may spare opioid requirements and offer more stable hemodynamics during neurosurgery [9] [10] [11] . Besides dexmedetomidine's well-proven sedative effects, an increasing body of both in vitro and in vivo evidence indicates that dexmedetomidine also exerts a cell-protective effect on nervous tissue under ischemic conditions [12] [13] [14] [15] .
In addition, laryngoscopy and endotracheal intubation are apt to result in hypertension, tachycardia and arrhythmias, which is hazardous to those patients undergoing neurosurgery for brain tumor [16, 17] . Therefore, it seems that dexmedetomidine used as an adjunct of anesthesia induction may be helpful to those patients undergoing neurosurgery. Dexmedetomidine loading infusion with the dosage of 1 g/kg over 10 min showed its efficacy and safety to several kinds of operation patients [18] [19] [20] . However，the efficacy and safety of dexmedetomidine loading infusion during anesthesia induction to those intracranial tumor patients remain unknown. The objective of this preliminary observational trial was to investigate into the sedative effects, respiration inhibition, hemodynamic changes and adverse effects of dexmedetomidine with a loading infusion dosage 1 g/kg over 10 min during introduction in neurosurgery patients.
Patients and Methods
This trial protocol was approved by the Ethics Committee of the General Hospital of PLA, Beijing, China. The written informed consents were obtained from all patients.
Sixty patients, male or female, aged 18 -60 years, with American Society of Anesthesiologists (ASA) physical status I or II, were enrolled from April 2011 to October 2011 in this trial. Among these patients, 30 patients were scheduled to intracranial tumor resection (Group N), and the other 30 patients were scheduled for abdominal operation (Group A). The exclusion criteria included: patients with hepatic or renal insufficiency, a history of allergy to α 2 -adrenoreceptor agonist, a psychiatric or neuromuscular disorder, or predicted difficult airway.
All the patients were premeditated with intramuscular atropine of 0.5 mg at 30 min before operation. After entering the operation room, patients were inserted intravenously catheter with a 20-or 22-gauge in a peripheral vein. The patients were first administered with a loading dosage of 1 g/kg of dexmedetomidine (200 g/ml, diluted with normal saline to 4 g/ml) over 10 min by a computer controlled pump infuser then followed to infuse with the rate of 0.5 g/kg/h. When loading infusion was ended, fentanyl 2 g/kg, propofol 2 mg/kg and rocuronium 0.9 mg/kg were sequentially administered within 1 min. Three minutes later, endotracheal intubation was performed by one of the two appointed attending anesthesiologists. Propofol and isoflurane were used for anesthesia maintenance.
Heart rate (HR), blood pressure (systolic and diastolic blood pressure, SBP and DBP), bispectral index (BIS) and pulse oxygen saturation (SpO 2 ) were recorded at the following time points: before dexmedetomidine loading infusion (T1), at the end of loading infusion (T2), before, during and 5 min after endotracheal intubation (T3-5, respectively).
Normally, during the period of loading infusion, the patients inhaled room air without extra-oxygen supplying. If a patient's HR < 45 bpm for >3 min, SBP < 80 mmHg for >3 min, or SpO 2 < 90% for >1 min, he (she) will drop out from this trial and then atropine, ephedrine or 100% oxygen via mask will be given [21] . The occurrence of adverse reactions including nausea and dry mouth were also noted.
Statistical Analysis
Data are presented as means ± SD or proportion. Statistical analysis was performed using the SPSS 17.0 software for Windows (Chicago, IL). Proportion was compared using chi-square test. Age, weight and height were compared using independent-samples t tests. HR, SBP, DBP, BIS and SpO 2 were analyzed by using analysis of variance for repeated measurements. P < 0.05 was considered to be statistically significant.
Result
All the surgeries were successfully completed. One patient from Group N was ceased to continue infusing dexmedetomidine because a severe headache occurred during the loading infusion. There was no significant difference with respect to demographic data between the two groups ( Table 1) .
As shown in Figure 1 , the HR of Group N is faster than that of Group A (83 ± 11 bpm vs. 75 ± 10 bpm, P < 0.01) before anesthesia. After loading infusion of dexmedetomidine at dosage of 1 g/kg, HR decreased significantly in both groups (the average HR of Group N was 62 bpm and Group A was 61 bpm independently, P < 0.01, compared with T1, Figure 1 ). However, there was no significant change in blood pressure during loading infusion or even during endotracheal intubation (Figure 2) .
Among with the infusion of dexmedetomidine, the patient could be sedated effectively. After loading infusion, it showed that patients were deep sedated (the average BIS value decreased from 94 to 74 in Group N, from 95 to 76 in Group A, P < 0.01, Figure 3) . In this trial, we designed that all patients were limited to inhale room air during dexmedetomidine loading infusion. The results showed that at the end of loading infusion SpO 2 value decreased from 98% to 95% of Group N and from 99% to 96% respectively (P < 0.01) (Figure 4) . Though no patient was dropped off in case of SpO 2 lower than 90% for more than 1 minute. However, it happened to some patients of both groups that their SpO 2 value were fluctuating between 86% -96%. Among them, 14 of 29 patients in Group N while 6 of 30 patients in Group A whose SpO 2 value dropped below 90% at least once during dexmedetomidine loading infusion (P < 0.05). There was no patient complained of the common adverse reactions in both groups, for example nausea or dry mouth. However, an 18-year-old male patient with pituitary tumor was dropped out from this trial because he suffered a serious headache after dexmedetomidine loading infusing for about 5 min. His headache disappeared within 2 min after the stop of dexmedetomidine infusing. In this episode, his SBP increased from 138 to 158 mmHg when headache occurred, and returned to 141 mmHg when headache disappeared.
Discussion
In this trial, we compared the efficacy of dexemdetomidine in a method of commonly used [22, 23] between neurosurgery and abdominal operation patients. The results showed that BP, SpO 2 and BIS had no significantly statistical difference between the two groups. However, during loading infusing of dexmedetomidine with 1 g/kg over 10 min, the intracranial tumor patients had a higher incidence of hypoxemia (SpO 2 < 90%) than those abdominal operation patients, and also dexmedetomidine Open Access PP
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A Preliminary Observational Trial 587 might induce serious headache in patients with intracranial tumor. Dexmedetomidine as an α 2 -adrenoceptor agonist is widely used for the sedation of intubated and mechanically ventilated patients in the intensive care setting, as well as for the sedation of non-intubated patients before and during surgical procedures [7, 24, 25] . In addition to its sedative properties, dexmedetomidine causes sympatholysis and decreases anesthetic requirements, which may decrease opioid use and make it attractive for use as an adjunct to general anesthesia. Moreover, the neuroprotective property of dexmedetomidine has been demonstrated in various animal models of cerebral ischemia [9, 26] . Drummond and colleagues [27] recently demonstrated a simultaneous decrease of CBF and CMRO 2 with dexmedetomidine in healthy volunteers. However, the cerebral blood flow (CBF)/cerebral metabolic rate (CMR) ratio did not decrease and suggest that CMR-CBF coupling is preserved during dexmedetomidine administration. Also, researchers found that dexmedetomidine could decrease the adrenergic response to the trauma of surgery and improve perioperative hemodynamic stability [28] . All these documents show that pretreatment or loading infusion with dexmedetomidine before induction has the advantage to those neurosurgery patients.
However, there are few researches on the safety of using dexmedetomidine to intracranial tumor patients and which dosage should be used as an adjunct to anesthesia induction, though it was recommended that dexmedetomidine 1 g/kg as loading infusion over 10 min was a common clinical dosage [22] . In this study, we designed a trial to investigate the safety and efficiency of dexmedetomidine usage to those intracranial patients who received a loading infusion dosage of 1 g/kg over 10 min as an adjunct to anesthesia induction. Additionally, patients were allowed to inhale room air but not the 100% O 2 during loading infusion during this trial to investigate the dexmedetomidine' effect on patients' respiration function.
The primary composite endpoint of this study was defined as patients having any of the following during loading infusion period: 1) HR < 45 bpm for >3 minutes, 2) systolic blood pressure (SBP) < 80 mmHg for >3 minutes, 3) or SpO 2 < 90% for >1 min, or 4) administration of vasoactive agents (including <500 μg phenylephrine by bolus or infusion, any epinephrine) or any atropine. It was found that the HR of almost all the patients including intracranial tumor patients and abdominal operation patients decreased obviously. The HR of some patients was less than 50 bpm (but haven't match the deadline of 45 bpm for more than 3 min) during dexmedetomidine loading infusion. In our study, the base HR of intracranial tumor patients was faster significantly than abdominal operation patients. It may be due to different treatments of diseases before operation. However, HR was almost the same of both groups at the end of dexmedetomidine loading infusion. In addition, the hemodynamic frustration changed slightly during dexmedetomidine infusion and even during endotracheal intubation.
It is of very important for patients to keep normal central respiratory rhythm during sedation or introduction of anesthesia. Dexmedetomidine, an α 2 -adrenergic agonist, causes an unique kind of sedation, acting on the subcortical areas, which resembles natural sleep without respiratory depression [29] . The monitoring of BIS value in our study showed that during dexmedetomidine loading infusion, patients could be sedated and reached a level of deep sleep gradually (the BIS of both group at the end of loading infusion <76, 0 = no cortical activity, or coma; 40 -60 = unconscious; 70 -90 = varying levels of conscious sedation; 100-fully awake). During loading infusion, patients could be still breathing almost normally. It was shown that SpO 2 could always keep beyond 90% when patients inhaling room air but not 100% oxygen. However, during dexmedetomidine loading infusion, some patients' SpO 2 decreased and fluctuated in a wide range between 86% and 96%. And the results could tell us that the incidence of hypoxemia (the SpO 2 was dropped below 90% at least one time) was much higher in those patients with intracranial tumor than those patients undergoing abdominal operation. In other words, our data implied that dexemdetomidine might lead to more serious respiration depression in patients with intracranial tumor. The reason why the incidence of hypoxemia was much higher in intracranial tumor patients than in abdominal patients may be due to the ICP changes of intracranial tumor patients, but still remains unclear.
Dexmedetomidine has been used in over one million patients since its approval in 1999 [30] . The most frequently reported adverse reactions of dexmetomidine usage were hypotension, nausea, and bradycardia [31] [32] [33] . In this study, during dexmedetomidine loading infusion, there was a young man suffered an unpredictable headache. The exact reason for headache happening was far to know, but the occurrence of headache warning us to notice this adverse reaction when dexemdetomidine used in clinics, particularly in patients with intracranial tumor. Sometimes, a higher loading infusion doses may be required to ensure adequate sedation. However, a higher dose of dexmedetomidine can have a higher incidence of hypertension, bradycardia, and hypotension [7, 34, 35] . Patients with intracranial tumor showed less endurance than those patients without intracranial tumor.
The main limitation of our study was the small sample size. The sample size was too small especially when observing adverse reactions. Therefore, further large sample size investigations are needed in the near future to determine the safety of dexemdetomidine in neurosurgery. Further studies are necessary to establish an optimal dosage regimen especially for patients underwent craniotomy, because those patients maybe always endure a high ICP and experience an unexpected adverse reaction. Secondly, we had not checked the precise sedation scores of patients and also had not recorded the frequent of respiration. Therefore, further investigations maybe need to answer these questions.
Conclusion
Compared with those without intracranial tumor patients, dexemdetomidine with a loading dosage 1 g/kg may induce more serious respiration depression and sometimes headache in intracranial tumor patients. And further investigations with a large sample size are needed to determine the safety rang of dexemdetomidine in intracranial tumor patients.
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